NAS:CERS (USA) Also Trade In: Germany

Cerus Corp $ 6.44 0.01 (0.16%)

Volume:
1,015,723
Avg Vol (1m):
1,476,503
Market Cap $:
1.07 Bil
Enterprise Value $:
997.53 Mil
P/E (TTM):
0.00
P/B:
9.35
Warning! GuruFocus has detected 3 Severe warning signs with CERS. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

CERS News and Headlines - Cerus Corp

GuruFocus Articles Total 3
  • 1

The guru increased his position in the last 2 quarters

Ron Baron (Trades, Portfolio) founded Baron Capital Management, an investment management firm. In both the first and second quarters, the guru invested in the following stocks:

Adamas Pharmaceuticals Inc. (ADMS)

In the first quarter, Baron increased his position by 81.87% and by 45.50% in the second quarter.

a7f08fc7e3669192558b07c9f768dc9d.png

The pharmaceutical company has a market cap of $479.33 million. Its revenue fell 90% over the last 12 months, but the stock price has risen 34% over the last several weeks.

Steven Cohen (Trades, Portfolio) is the company's largest shareholder among the

242 Views    Tiziano Frateschi    2017-09-07 20:56
Guru stock highlight

Cerus Corporation (NASDAQ:CERS) has an FDA and EU approved device that inactivates pathogens such as viruses and bacteria in donated blood. Current regulatory approvals cover use of the Cerus device for platelets and plasma from donated blood (an $800 million worldwide, and $350 million U.S. market opportunity, for which Cerus has signed up over 80% of all U.S. blood centers). If additional approvals for usage with red blood cell (RBC) components are obtained, Cerus will add an estimated $2.5 billion in market opportunity ($1 billion in the U.S., in the same blood centers), for which there is no current

150 Views    Holly LaFon    2017-01-20 21:18
Guru stock highlight

Cerus Corporation (CERS) is a leading provider of medical equipment to the blood banking industry. Its equipment performs pathogen inactivation (PI) on donated blood, preventing infections via transfused blood caused by viruses and bacteria in donated units. Cerus gained significantly in the fourth quarter as it started to gain contracts with a significant number of U.S. blood centers for PI in platelets and plasma. We believe that Cerus has what is likely to be an insurmountable lead in the U.S., and market leading E.U. position for its products. We should see substantial growth for years to come as we expect

514 Views    Holly LaFon    2016-02-25 21:35

Headlines Total 21
  • 1

2020-08-26 $ 6.39 (1.11%)
12:08pm
2020-08-25 $ 6.32 (-7.47%)
5:19am
2020-08-04 $ 7.47 (0.81%)
4:15pm
2020-07-28 $ 6.77 (-0.44%)
11:33am
2020-06-17 $ 6.18 (-1.44%)
10:30am
2020-05-27 $ 5.95 (-0.17%)
11:00am
2020-05-12 $ 5.46 (-0.18%)
8:28pm
2020-05-06 $ 5.34 (2.69%)
10:56pm
2020-05-05 $ 5.34 (2.69%)
5:45pm
2020-04-29 $ 6.14 (2.16%)
12:38pm
9:05am
2020-04-28 $ 6.01 (-2.44%)
11:34am
2020-04-23 $ 5.37 (0.94%)
10:43am
2018-10-18 $ 6.77 (1.2%)
11:00am
2018-05-15 $ 6.45 (-1.98%)
11:01am
2017-01-20 $ 4.39 (1.86%)
3:18pm
2016-02-25 $ 4.98 (-2.35%)
3:35pm
2011-03-16 $ 2.47 (-1.98%)
4:34pm
2010-08-16 $ 2.98 (4.2%)
6:14am
2010-05-12 $ 3.06 (2.68%)
3:16pm
2009-11-06 $ 1.94 (3.19%)
4:24pm
Total 21
  • 1